AVI BioPharma, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for AVI BioPharma, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

AVI BioPharma, Inc.. The Company's principal activity is to develop therapeutic products for the treatment of life-threatening diseases using third-generation NeuGene antisense drugs and ESPRIT exon skipping technology. NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, its antiviral program uses NeuGene antisense compounds to combat disease by targeting single-stranded RNA viruses, including dengue virus, Ebola virus and H5N1 avian influenza virus. The NeuGene-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. The trademark drugs include NeuGene(R), Avicine(R), Resten-NG(R), Resten-CPTM, and Oncomyc-NGTM.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report